Exact Mass: 375.2257

Exact Mass Matches: 375.2257

Found 127 metabolites which its exact mass value is equals to given mass value 375.2257, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Pipamperone

1-[4-(4-fluorophenyl)-4-oxobutyl]-[1,4-bipiperidine]-4-carboxamide

C21H30FN3O2 (375.2322)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AD - Butyrophenone derivatives D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent Pipamperone (Floropipamide; McN-JR 3345; R 3345) is a high-affinity antagonist of 5-HT2A receptor (pKi=8.2) and D4 receptor (pKi=8.0) and a low-affinity antagonist of D2 receptor (pKi=6.7)[1].

   

Phe-Pro-Ile

2-({[1-(2-amino-3-phenylpropanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylpentanoic acid

C20H29N3O4 (375.2158)


   

Bacithrocin B 2

Bacithrocin B 2

C19H29N5O3 (375.227)


   

Pipamperone

Pipamperone

C21H30FN3O2 (375.2322)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AD - Butyrophenone derivatives D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent CONFIDENCE standard compound; INTERNAL_ID 2514 Pipamperone (Floropipamide; McN-JR 3345; R 3345) is a high-affinity antagonist of 5-HT2A receptor (pKi=8.2) and D4 receptor (pKi=8.0) and a low-affinity antagonist of D2 receptor (pKi=6.7)[1].

   

RCS-8

1-(1-(2-cyclohexylethyl)-1H-indol-3-yl)-2-(2-methoxyphenyl)ethanone

C25H29NO2 (375.2198)


   

pyrrole-2-carboxylic acid 9-hydroxymethyl-7-(6-oxo-piperidin-2-yl)-octahydro-quinolizin-2-yl ester

pyrrole-2-carboxylic acid 9-hydroxymethyl-7-(6-oxo-piperidin-2-yl)-octahydro-quinolizin-2-yl ester

C20H29N3O4 (375.2158)


   

N-Methyl-triphyophyllin

N-Methyl-triphyophyllin

C25H29NO2 (375.2198)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

4,4-bis(dimethylamino)-4-(methylamino)trityl alcohol

4,4-bis(dimethylamino)-4-(methylamino)trityl alcohol

C24H29N3O (375.2311)


   
   

6-Benzyl 2-tert-butyl 2,6,9-triazaspiro[4.5]decane-2,6-dicarboxylate

6-Benzyl 2-tert-butyl 2,6,9-triazaspiro[4.5]decane-2,6-dicarboxylate

C20H29N3O4 (375.2158)


   
   

TERT-BUTYL 4-(1-(BENZYLOXYCARBONYL)AZETIDIN-3-YL)PIPERAZINE-1-CARBOXYLATE

TERT-BUTYL 4-(1-(BENZYLOXYCARBONYL)AZETIDIN-3-YL)PIPERAZINE-1-CARBOXYLATE

C20H29N3O4 (375.2158)


   

Difeterol

2-[2-benzhydryloxyethyl(methyl)amino]-1-phenylpropan-1-ol

C25H29NO2 (375.2198)


C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist

   

9-Benzyl 2-Tert-Butyl 2,6,9-Triazaspiro[4.5]Decane-2,9-Dicarboxylate

9-Benzyl 2-Tert-Butyl 2,6,9-Triazaspiro[4.5]Decane-2,9-Dicarboxylate

C20H29N3O4 (375.2158)


   

p-cyanophenyl trans-p-(4-pentylcyclohexyl)benzoate

p-cyanophenyl trans-p-(4-pentylcyclohexyl)benzoate

C25H29NO2 (375.2198)


   

tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,5-dihydro-2H-1,4-benzoxazepine-4-carboxylate

tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,5-dihydro-2H-1,4-benzoxazepine-4-carboxylate

C20H30BNO5 (375.2217)


   

Jasmolin II

Jasmolin II

C22H31O5 (375.2171)


   

6-(4-Methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(Z)-2- phenylvinyl]-4-pyrimidinamine

6-(4-Methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(Z)-2- phenylvinyl]-4-pyrimidinamine

C21H25N7 (375.2171)


   

benzyl 3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]azetidin-1-yl]pyrrolidine-1-carboxylate

benzyl 3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]azetidin-1-yl]pyrrolidine-1-carboxylate

C20H29N3O4 (375.2158)


   

(2r,6s)-6-{[methyl(3,4,5-Trimethoxyphenyl)amino]methyl}-1,2,5,6,7,8-Hexahydroquinazoline-2,4-Diamine

(2r,6s)-6-{[methyl(3,4,5-Trimethoxyphenyl)amino]methyl}-1,2,5,6,7,8-Hexahydroquinazoline-2,4-Diamine

C19H29N5O3 (375.227)


   

resolvin D1(1-)

resolvin D1(1-)

C22H31O5- (375.2171)


   

(4Z,7S,8E,10Z,12E,14E,16R,17S,19Z)-7,16,17-trihydroxydocosa-4,8,10,12,14,19-hexaenoate

(4Z,7S,8E,10Z,12E,14E,16R,17S,19Z)-7,16,17-trihydroxydocosa-4,8,10,12,14,19-hexaenoate

C22H31O5- (375.2171)


   

aspirin triggered resolvin D1

aspirin triggered resolvin D1

C22H31O5- (375.2171)


   

aspirin triggered resolvin D3

aspirin triggered resolvin D3

C22H31O5- (375.2171)


   

(4S,5E,7Z,10Z,13Z,15E,17R,19Z)-4-hydroperoxy17-hydroxydocosa-5,7,10,13,15,19-hexaenoate

(4S,5E,7Z,10Z,13Z,15E,17R,19Z)-4-hydroperoxy17-hydroxydocosa-5,7,10,13,15,19-hexaenoate

C22H31O5- (375.2171)


   

(4S,5E,7Z,10Z,13Z,15E,17S,19Z)-4-hydroperoxy-17-hydroxydocosa-5,7,10,13,15,19-hexaenoate

(4S,5E,7Z,10Z,13Z,15E,17S,19Z)-4-hydroperoxy-17-hydroxydocosa-5,7,10,13,15,19-hexaenoate

C22H31O5- (375.2171)


   

(4Z,7S,8E,10Z,13E,15Z,17S,19Z)7-hydroperoxy-17-hydroxydocosa-4,8,10,13,15,19-hexaenoate

(4Z,7S,8E,10Z,13E,15Z,17S,19Z)7-hydroperoxy-17-hydroxydocosa-4,8,10,13,15,19-hexaenoate

C22H31O5- (375.2171)


   

(7S,17R)-17-hydroxy-7-hydroperoxydocosahexaenoate

(7S,17R)-17-hydroxy-7-hydroperoxydocosahexaenoate

C22H31O5- (375.2171)


   

4S,11R,17S-trihydroxy-5Z,7E,9E,13Z,15E,19Z-docosahexaenoate

4S,11R,17S-trihydroxy-5Z,7E,9E,13Z,15E,19Z-docosahexaenoate

C22H31O5- (375.2171)


   

aspirin triggered resolvin D2

aspirin triggered resolvin D2

C22H31O5- (375.2171)


   

4S,5R-17S-resolvin

4S,5R-17S-resolvin

C22H31O5- (375.2171)


   

aspirin triggered resolvin D4

aspirin triggered resolvin D4

C22H31O5- (375.2171)


   
   

1-[1-[(4-Hydroxy-1-piperidinyl)-oxomethyl]cyclohexyl]-3-(2-methoxyphenyl)urea

1-[1-[(4-Hydroxy-1-piperidinyl)-oxomethyl]cyclohexyl]-3-(2-methoxyphenyl)urea

C20H29N3O4 (375.2158)


   

2-[[4-(3,5-Ditert-butylpyrazol-1-yl)phenyl]iminomethyl]phenol

2-[[4-(3,5-Ditert-butylpyrazol-1-yl)phenyl]iminomethyl]phenol

C24H29N3O (375.2311)


   

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

C20H29N3O4 (375.2158)


   
   
   
   
   
   
   
   
   
   
   

N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide

N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide

C20H29N3O4 (375.2158)


   

2-[(2S,3S,6R)-2-(hydroxymethyl)-3-(propylcarbamoylamino)-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

2-[(2S,3S,6R)-2-(hydroxymethyl)-3-(propylcarbamoylamino)-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

C20H29N3O4 (375.2158)


   

2-[(2S,3S,6S)-2-(hydroxymethyl)-3-(propylcarbamoylamino)-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

2-[(2S,3S,6S)-2-(hydroxymethyl)-3-(propylcarbamoylamino)-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

C20H29N3O4 (375.2158)


   

N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide

N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide

C20H29N3O4 (375.2158)


   

N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide

N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide

C20H29N3O4 (375.2158)


   

N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide

N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide

C20H29N3O4 (375.2158)


   

N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide

N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide

C20H29N3O4 (375.2158)


   

2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

C20H29N3O4 (375.2158)


   

2-[(2S,3R,6S)-2-(hydroxymethyl)-3-(propylcarbamoylamino)-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

2-[(2S,3R,6S)-2-(hydroxymethyl)-3-(propylcarbamoylamino)-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

C20H29N3O4 (375.2158)


   

2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

C20H29N3O4 (375.2158)


   

2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

C20H29N3O4 (375.2158)


   

2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

C20H29N3O4 (375.2158)


   

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

C20H29N3O4 (375.2158)


   

N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

C20H29N3O4 (375.2158)


   

N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

C20H29N3O4 (375.2158)


   

N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide

N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide

C20H29N3O4 (375.2158)


   

N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide

N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide

C20H29N3O4 (375.2158)


   

2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide

C20H29N3O4 (375.2158)


   

N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

C20H29N3O4 (375.2158)


   

N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

C20H29N3O4 (375.2158)


   

N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

C20H29N3O4 (375.2158)


   

N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide

C20H29N3O4 (375.2158)


   

N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide

N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide

C20H29N3O4 (375.2158)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

10(R),17(S),20-trihydroxydocosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoate

10(R),17(S),20-trihydroxydocosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoate

C22H31O5- (375.2171)


   

4-[2,3-Di(butanoyloxy)propoxy]-2-(trimethylazaniumyl)butanoate

4-[2,3-Di(butanoyloxy)propoxy]-2-(trimethylazaniumyl)butanoate

C18H33NO7 (375.2257)


   

4-(3-Acetyloxy-2-hexanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

4-(3-Acetyloxy-2-hexanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

C18H33NO7 (375.2257)


   

4-(2-Pentanoyloxy-3-propanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

4-(2-Pentanoyloxy-3-propanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

C18H33NO7 (375.2257)


   

resolvin D2(1-)

resolvin D2(1-)

C22H31O5 (375.2171)


A polyunsaturated fatty acid anion that is the conjugate base of resolvin D2, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

22-hydroxyprotectin D1(1-)

22-hydroxyprotectin D1(1-)

C22H31O5 (375.2171)


A docosanoid anion that is the conjugate base of 22-hydroxyprotectin D1, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

LML134

LML134

C19H29N5O3 (375.227)


LML134 (compound 18b) is an orally active and high selective Histamine 3 receptor (H3R) inverse agonist with Kis of 0.3 nM and 12 nM for hH3R cAMP and hH3R bdg. LML134 penetrates the brain rapidly, leading to high H3R occupancy, and disengages its target with a fast kinetic profile. LML134 has the potential for excessive sleep disorders[1].

   

(2r,7r,9r,9as)-7-[(2r)-6-hydroxy-2,3,4,5-tetrahydropyridin-2-yl]-9-(hydroxymethyl)-octahydro-1h-quinolizin-2-yl 1h-pyrrole-2-carboxylate

(2r,7r,9r,9as)-7-[(2r)-6-hydroxy-2,3,4,5-tetrahydropyridin-2-yl]-9-(hydroxymethyl)-octahydro-1h-quinolizin-2-yl 1h-pyrrole-2-carboxylate

C20H29N3O4 (375.2158)


   

(2s)-n-(5-carbamimidamido-1-oxopentan-2-yl)-2-[(1-hydroxy-2-methylpropylidene)amino]-3-phenylpropanimidic acid

(2s)-n-(5-carbamimidamido-1-oxopentan-2-yl)-2-[(1-hydroxy-2-methylpropylidene)amino]-3-phenylpropanimidic acid

C19H29N5O3 (375.227)


   

7-(6-hydroxy-2,3,4,5-tetrahydropyridin-2-yl)-9-(hydroxymethyl)-octahydro-1h-quinolizin-2-yl 1h-pyrrole-2-carboxylate

7-(6-hydroxy-2,3,4,5-tetrahydropyridin-2-yl)-9-(hydroxymethyl)-octahydro-1h-quinolizin-2-yl 1h-pyrrole-2-carboxylate

C20H29N3O4 (375.2158)